180 related articles for article (PubMed ID: 30692213)
21. Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.
Gadi D; Martindale SP; Chiu PY; Khalsa J; Chen PH; Fernandes SM; Wang Z; Tyekucheva S; Machado JH; Fisher DC; Armand P; Davids MS; Rodig S; Sherry B; Brown JR
Blood Cancer J; 2023 Feb; 13(1):22. PubMed ID: 36732326
[TBL] [Abstract][Full Text] [Related]
22. PKC-θ is an important driver of fluoride-induced immune imbalance of regulatory T cells/effector T cells.
Zhu S; Liu B; Fu G; Yang L; Wei D; Zhang L; Zhang Q; Gao Y; Sun D; Wei W
Sci Total Environ; 2024 Jul; 934():173081. PubMed ID: 38754514
[TBL] [Abstract][Full Text] [Related]
23. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.
Williams O; Houseman BT; Kunkel EJ; Aizenstein B; Hoffman R; Knight ZA; Shokat KM
Chem Biol; 2010 Feb; 17(2):123-34. PubMed ID: 20189103
[TBL] [Abstract][Full Text] [Related]
24. Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia.
Ravi SN; Choi IW; Ngapgue EK; Stroiney AG; Miranda CJ
Cureus; 2024 May; 16(5):e59541. PubMed ID: 38826911
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel pyrido[3,2-d]pyrimidine derivatives as selective and potent PI3Kδ inhibitors.
Bai H; Sun J; Lei H; Zhang SQ; Yuan B; Ma M; Xin M
Drug Dev Res; 2023 Dec; 84(8):1709-1723. PubMed ID: 37732677
[TBL] [Abstract][Full Text] [Related]
26. Discovery of Novel Azaindoles as Potent and Selective PI3Kδ Inhibitors for Treatment of Multiple Sclerosis.
Yu M; Wang X; Tang Y; Wang L; Hu X; Weng Q; Wang J; Cui S
J Med Chem; 2024 Jun; 67(11):9628-9644. PubMed ID: 38754045
[TBL] [Abstract][Full Text] [Related]
27. Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.
Lim EL; Okkenhaug K
Immunology; 2019 Jul; 157(3):210-218. PubMed ID: 31107985
[TBL] [Abstract][Full Text] [Related]
28. PI3K Isoform Immunotherapy for Solid Tumours.
Scott J; Rees L; Gallimore A; Lauder SN
Curr Top Microbiol Immunol; 2022; 436():369-392. PubMed ID: 36243853
[TBL] [Abstract][Full Text] [Related]
29. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer.
Ali K; Soond DR; Pineiro R; Hagemann T; Pearce W; Lim EL; Bouabe H; Scudamore CL; Hancox T; Maecker H; Friedman L; Turner M; Okkenhaug K; Vanhaesebroeck B
Nature; 2014 Jun; 510(7505):407-411. PubMed ID: 24919154
[TBL] [Abstract][Full Text] [Related]
30. Pegylated-liposomes increase the efficacy of Idelalisib in lymphoma B-cells.
Maroni G; Tomassi E; Valenti D; Fernàndez-Busquets X; Pucci L; Levantini E; Caddeo C
Int J Pharm; 2024 May; 657():124144. PubMed ID: 38653342
[TBL] [Abstract][Full Text] [Related]
31. Quantitative systems pharmacology model-based investigation of adverse gastrointestinal events associated with prolonged treatment with PI3-kinase inhibitors.
Gadkar K; Friedrich C; Hurez V; Ruiz ML; Dickmann L; Kumar Jolly M; Schutt L; Jin J; Ware JA; Ramanujan S
CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):616-627. PubMed ID: 34850607
[TBL] [Abstract][Full Text] [Related]
32. PI3Kδ Mediates Fibrosis by Patient-Derived Vitreous.
Liu D; Yan B; Yin Y; Chen F; Guo C; Li Q; Liu J; Pu L; Wu W; Luo J
Lab Invest; 2024 Apr; 104(4):102026. PubMed ID: 38307209
[TBL] [Abstract][Full Text] [Related]
33. Activated PI3Kδ Specifically Perturbs Mouse Regulatory T Cell Homeostasis and Function Leading to Immune Dysregulation.
Singh AK; Al Qureshah F; Drow T; Hou B; Rawlings DJ
J Immunol; 2024 Jun; ():. PubMed ID: 38829130
[TBL] [Abstract][Full Text] [Related]
34. Activated PI3Kδ specifically perturbs mouse Treg homeostasis and function leading to immune dysregulation.
Singh AK; Qureshah FA; Drow T; Hou B; Rawlings DJ
bioRxiv; 2023 Dec; ():. PubMed ID: 38187650
[TBL] [Abstract][Full Text] [Related]
35. A Novel Role for the Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Delta Isoform in Hepatocellular Proliferation.
Martucci NJ; Stoops J; Bowen W; Orr A; Cotner MC; Michalopoulos GK; Bhushan B; Mars WM
Am J Pathol; 2024 May; ():. PubMed ID: 38705383
[TBL] [Abstract][Full Text] [Related]
36. Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler S; Ramírez-Suástegui C; Li Y; King E; Chudley L; Thomas J; Wood O; von Witzleben A; Jeffrey D; McCann K; Simon H; Mondal M; Wang A; Dicker M; Lopez-Guadamillas E; Chou TF; Dobbs NA; Essame L; Acton G; Kelly F; Halbert G; Sacco JJ; Schache AG; Shaw R; McCaul JA; Paterson C; Davies JH; Brennan PA; Singh RP; Loadman PM; Wilson W; Hackshaw A; Seumois G; Okkenhaug K; Thomas GJ; Jones TM; Ay F; Friberg G; Kronenberg M; Vanhaesebroeck B; Vijayanand P; Ottensmeier CH
Nature; 2022 May; 605(7911):741-746. PubMed ID: 35508656
[TBL] [Abstract][Full Text] [Related]
37. Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant
Ha S; Wang BD
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831678
[TBL] [Abstract][Full Text] [Related]
38. Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines.
Sklarz LM; Gladbach YS; Ernst M; Hamed M; Roolf C; Sender S; Beck J; Schütz E; Fischer S; Struckmann S; Junghanss C; Fuellen G; Murua Escobar H
Cancer Cell Int; 2020; 20():390. PubMed ID: 32817744
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of idelalisib in chronic lymphocytic leukemia and follicular lymphoma disclose better outcomes for patients with lower exposure.
Despas F; Chaouki M; de Barros S; Bonneau B; Allal B; Guillermet-Guibert J; Ysebaert L
Leuk Lymphoma; 2024 May; ():1-3. PubMed ID: 38747179
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
